<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Pancreatic Cancer Genomics | Cristea Lab</title>
    <link rel="stylesheet" href="../styles-warm-accent.css">
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css">
    <style>
        .research-page {
            margin-top: 100px;
            padding: 3rem 0;
        }
        .research-hero {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            padding: 4rem 0;
            text-align: center;
            margin-bottom: 4rem;
        }
        .research-hero h1 {
            font-size: 3rem;
            margin-bottom: 1rem;
        }
        .research-hero p {
            font-size: 1.3rem;
            max-width: 800px;
            margin: 0 auto;
            opacity: 0.9;
        }
        .research-section {
            margin-bottom: 4rem;
        }
        .research-section h2 {
            font-size: 2.5rem;
            color: var(--primary-color);
            margin-bottom: 2rem;
            border-bottom: 3px solid var(--primary-color);
            padding-bottom: 0.5rem;
        }
        .project-card {
            background: white;
            border-radius: 15px;
            box-shadow: var(--shadow);
            padding: 2.5rem;
            margin-bottom: 2rem;
            border-left: 5px solid var(--accent-color);
            transition: var(--transition);
        }
        .project-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 15px 35px rgba(0, 0, 0, 0.15);
        }
        .project-card h3 {
            font-size: 1.8rem;
            color: var(--primary-color);
            margin-bottom: 1rem;
        }
        .project-card h4 {
            font-size: 1.3rem;
            color: var(--accent-color);
            margin-bottom: 1rem;
            font-weight: 600;
        }
        .project-description {
            font-size: 1.1rem;
            line-height: 1.7;
            margin-bottom: 1.5rem;
        }
        .project-details {
            background: var(--bg-light);
            padding: 1.5rem;
            border-radius: 10px;
            margin: 1.5rem 0;
        }
        .project-details h5 {
            color: var(--primary-color);
            margin-bottom: 1rem;
        }
        .methodology-list {
            list-style: none;
            padding: 0;
        }
        .methodology-list li {
            padding: 0.5rem 0;
            border-bottom: 1px solid #eee;
        }
        .methodology-list li:last-child {
            border-bottom: none;
        }
        .methodology-list li::before {
            content: 'ðŸ”¬';
            margin-right: 0.5rem;
        }
        .impact-highlight {
            background: linear-gradient(135deg, #f8f9fa, #e9ecef);
            padding: 2rem;
            border-radius: 15px;
            border-left: 5px solid var(--secondary-color);
            margin: 2rem 0;
        }
        .impact-highlight h4 {
            color: var(--secondary-color);
            margin-bottom: 1rem;
        }
        .tech-stack {
            display: flex;
            flex-wrap: wrap;
            gap: 0.5rem;
            margin: 1rem 0;
        }
        .tech-tag {
            background: var(--primary-color);
            color: white;
            padding: 0.3rem 0.8rem;
            border-radius: 15px;
            font-size: 0.9rem;
            font-weight: 500;
        }
        .immune-highlight {
            background: linear-gradient(135deg, #e8f5e8, #c8e6c9);
            padding: 2rem;
            border-radius: 15px;
            border-left: 5px solid #4caf50;
            margin: 2rem 0;
        }
        .immune-highlight h4 {
            color: #2e7d32;
            margin-bottom: 1rem;
        }
        .drug-highlight {
            background: linear-gradient(135deg, #fff3e0, #ffe0b2);
            padding: 2rem;
            border-radius: 15px;
            border-left: 5px solid #ff9800;
            margin: 2rem 0;
        }
        .drug-highlight h4 {
            color: #f57c00;
            margin-bottom: 1rem;
        }
        .resistance-analysis {
            background: linear-gradient(135deg, #fce4ec, #f8bbd9);
            padding: 2rem;
            border-radius: 15px;
            border-left: 5px solid #e91e63;
            margin: 2rem 0;
        }
        .resistance-analysis h4 {
            color: #c2185b;
            margin-bottom: 1rem;
        }
        .clinical-application {
            background: linear-gradient(135deg, #fff3e0, #ffe0b2);
            padding: 2rem;
            border-radius: 15px;
            border-left: 5px solid #ff9800;
            margin: 2rem 0;
        }
        .clinical-application h4 {
            color: #f57c00;
            margin-bottom: 1rem;
        }
        .data-integration-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 1.5rem;
            margin: 2rem 0;
        }
        .data-type-card {
            background: white;
            padding: 1.5rem;
            border-radius: 10px;
            box-shadow: var(--shadow);
            border-top: 4px solid var(--accent-color);
            text-align: center;
        }
        .screen-results-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 1.5rem;
            margin: 2rem 0;
        }
        .screen-result-card {
            background: white;
            padding: 1.5rem;
            border-radius: 10px;
            box-shadow: var(--shadow);
            border-top: 4px solid var(--accent-color);
            text-align: center;
        }
        .target-discovery {
            background: linear-gradient(135deg, #e3f2fd, #bbdefb);
            padding: 2rem;
            border-radius: 15px;
            border-left: 5px solid #2196f3;
            margin: 2rem 0;
        }
        .target-discovery h4 {
            color: #1976d2;
            margin-bottom: 1rem;
        }
        .overview-grid {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 2rem;
            margin: 2rem 0;
        }
        @media (max-width: 768px) {
            .overview-grid {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>
<body>
    <!-- Navigation -->
    <nav class="navbar">
        <div class="nav-container">
            <div class="nav-brand">
                <h1>Cristea Lab</h1>
                <span class="nav-subtitle">AI Cancer Genomics Research</span>
            </div>
            <ul class="nav-menu">
                <li><a href="../index.html" class="nav-link">Home</a></li>
                <li><a href="../index.html#research" class="nav-link">Research</a></li>
                <li><a href="../team.html" class="nav-link">Team</a></li>
                <li><a href="../publications.html" class="nav-link">Publications</a></li>
                <li><a href="../index.html#software" class="nav-link">Software</a></li>
                <li><a href="../index.html#contact" class="nav-link">Contact</a></li>
            </ul>
            <div class="nav-toggle">
                <span class="bar"></span>
                <span class="bar"></span>
                <span class="bar"></span>
            </div>
        </div>
    </nav>

    <!-- Research Page Content -->
    <div class="research-page">
        <!-- Hero Section -->
        <div class="research-hero">
            <div class="container">
                <h1>Pancreatic Cancer Genomics</h1>
                <p>
                    Comprehensive genomic and immune profiling to understand pancreatic cancer biology, 
                    predict treatment responses, and develop novel therapeutic strategies through integrative 
                    analysis of multi-modal data from clinical trials and patient samples.
                </p>
            </div>
        </div>

        <div class="container">
            <!-- Overview -->
            <div class="research-section">
                <h2>Research Overview</h2>
                <div class="project-description">
                    Our pancreatic cancer genomics research combines cutting-edge technologies in immune profiling, 
                    drug discovery, and computational analysis to tackle one of the most challenging cancers. We 
                    integrate single-cell technologies, CRISPR screening, proteomics, and AI-driven approaches to 
                    understand disease mechanisms and develop new therapeutic strategies.
                </div>
                
                <div class="overview-grid">
                    <div class="immune-highlight">
                        <h4>Immunotherapy Revolution</h4>
                        <p>
                            While immunotherapy has transformed treatment for many cancers, pancreatic cancer remains largely 
                            resistant to these approaches. Our research aims to overcome this resistance by understanding the 
                            unique immune landscape of pancreatic tumors and identifying combination strategies that can 
                            make immunotherapy effective in this challenging cancer type.
                        </p>
                    </div>
                    
                    <div class="drug-highlight">
                        <h4>KRAS: The "Undruggable" Target</h4>
                        <p>
                            KRAS has long been considered "undruggable" due to its smooth protein surface and high affinity 
                            for its substrate. Recent breakthroughs in KRAS inhibitor development have opened new therapeutic 
                            possibilities for pancreatic cancer patients, but resistance inevitably emerges. Our research 
                            aims to stay ahead of resistance by understanding its mechanisms and developing combination 
                            strategies to prevent or overcome it.
                        </p>
                    </div>
                </div>

                <div class="data-integration-grid">
                    <div class="data-type-card">
                        <i class="fas fa-dna" style="font-size: 2rem; color: var(--primary-color); margin-bottom: 1rem;"></i>
                        <h4>Single-cell RNA-seq</h4>
                        <p>Comprehensive immune cell profiling</p>
                    </div>
                    <div class="data-type-card">
                        <i class="fas fa-shield-virus" style="font-size: 2rem; color: var(--primary-color); margin-bottom: 1rem;"></i>
                        <h4>TCR Sequencing</h4>
                        <p>T-cell receptor repertoire analysis</p>
                    </div>
                    <div class="data-type-card">
                        <i class="fas fa-cut" style="font-size: 2rem; color: var(--primary-color); margin-bottom: 1rem;"></i>
                        <h4>CRISPR Screening</h4>
                        <p>Systematic vulnerability discovery</p>
                    </div>
                    <div class="data-type-card">
                        <i class="fas fa-chart-line" style="font-size: 2rem; color: var(--primary-color); margin-bottom: 1rem;"></i>
                        <h4>Mass Spectrometry</h4>
                        <p>Proteomics & post-translational analysis</p>
                    </div>
                    <div class="data-type-card">
                        <i class="fas fa-user-md" style="font-size: 2rem; color: var(--primary-color); margin-bottom: 1rem;"></i>
                        <h4>Clinical Data</h4>
                        <p>Treatment outcomes and survival</p>
                    </div>
                    <div class="data-type-card">
                        <i class="fas fa-microscope" style="font-size: 2rem; color: var(--primary-color); margin-bottom: 1rem;"></i>
                        <h4>Spatial Analysis</h4>
                        <p>Tumor-immune interactions</p>
                    </div>
                </div>
            </div>

            <!-- Immune Profiling Section -->
            <div class="research-section">
                <h2>Immune Profiling & Surveillance</h2>
                
                <!-- Project: Tumor and Blood Analysis -->
                <div class="project-card">
                    <h3>Integrative Analysis of Tumor and Blood</h3>
                    <h4>Immunotherapy-Treated Pancreatic Cancer Patients</h4>
                    <div class="project-description">
                        We perform comprehensive integrative analysis of tumor tissue and peripheral blood from pancreatic 
                        cancer patients treated with immunotherapy. This dual-compartment approach reveals how systemic 
                        immune responses correlate with local tumor immune environments and treatment outcomes.
                    </div>
                    
                    <div class="project-details">
                        <h5>Multi-compartment Analysis</h5>
                        <ul class="methodology-list">
                            <li>Simultaneous analysis of tumor-infiltrating and circulating immune cells</li>
                            <li>Longitudinal tracking of immune responses during treatment</li>
                            <li>Integration of single-cell transcriptomics with TCR repertoire data</li>
                            <li>Identification of shared vs. compartment-specific immune signatures</li>
                            <li>Correlation with clinical response and survival outcomes</li>
                        </ul>
                    </div>

                    <div class="clinical-application">
                        <h4>Clinical Translation</h4>
                        <p>
                            This research enables the development of liquid biopsy-based biomarkers for immunotherapy 
                            response prediction. By analyzing peripheral blood samples, we can non-invasively monitor 
                            treatment responses and adjust therapeutic strategies in real-time, improving patient outcomes 
                            while reducing the need for invasive tumor biopsies.
                        </p>
                    </div>

                    <div class="tech-stack">
                        <span class="tech-tag">Immunotherapy</span>
                        <span class="tech-tag">Liquid Biopsy</span>
                        <span class="tech-tag">Multi-compartment Analysis</span>
                        <span class="tech-tag">Longitudinal Profiling</span>
                        <span class="tech-tag">Biomarker Discovery</span>
                    </div>
                </div>

                <!-- Project: ImmunoProfiler -->
                <div class="project-card">
                    <h3>Foundation Models for Immunotherapy Response Prediction</h3>
                    <div class="project-description">
                        We develop and apply foundation models for computational pathology to predict patient outcomes 
                        after treatment with immune checkpoint blockade. Using the ImmunoProfiler dataset from DFCI, 
                        we integrate histopathology images with immune profiling data to create comprehensive predictive models.
                    </div>

                    <div class="project-details">
                        <h5>Computational Pathology Integration</h5>
                        <ul class="methodology-list">
                            <li>Foundation model analysis of H&E stained tumor sections</li>
                            <li>Automated immune cell detection and quantification</li>
                            <li>Integration with molecular immune profiling data</li>
                            <li>Multi-modal predictive modeling for treatment response</li>
                            <li>Validation across multiple cancer types and treatment regimens</li>
                        </ul>
                    </div>

                    <div class="tech-stack">
                        <span class="tech-tag">Foundation Models</span>
                        <span class="tech-tag">Computational Pathology</span>
                        <span class="tech-tag">Checkpoint Blockade</span>
                        <span class="tech-tag">Predictive Modeling</span>
                        <span class="tech-tag">ImmunoProfiler</span>
                    </div>
                </div>
            </div>

            <!-- Drug Discovery Section -->
            <div class="research-section">
                <h2>Drug Discovery & KRAS Inhibition</h2>
                
                <!-- Project: Resistance Mechanisms -->
                <div class="project-card">
                    <h3>Mechanisms of KRAS Inhibition Resistance</h3>
                    <h4>Whole Exome Sequencing and Bulk Genomics Analysis</h4>
                    <div class="project-description">
                        We perform comprehensive genomic analysis of pancreatic cancer models and patient samples that 
                        have developed resistance to KRAS inhibitors. This work identifies genetic alterations that 
                        drive resistance and reveals potential therapeutic targets to overcome resistance mechanisms.
                    </div>
                    
                    <div class="project-details">
                        <h5>Resistance Analysis Pipeline</h5>
                        <ul class="methodology-list">
                            <li>Longitudinal whole exome sequencing of resistant tumor samples</li>
                            <li>Comparative genomics between sensitive and resistant cell lines</li>
                            <li>Identification of resistance-associated mutations and copy number alterations</li>
                            <li>Pathway analysis of resistance mechanisms</li>
                            <li>Validation of resistance drivers through functional studies</li>
                        </ul>
                    </div>

                    <div class="resistance-analysis">
                        <h4>Key Resistance Mechanisms Identified</h4>
                        <p>
                            Our analysis has revealed multiple pathways through which pancreatic cancers can escape 
                            KRAS inhibition, including reactivation of downstream signaling pathways, activation 
                            of alternative oncogenic drivers, and metabolic reprogramming. Understanding these 
                            mechanisms enables the development of rational combination therapies.
                        </p>
                    </div>

                    <div class="tech-stack">
                        <span class="tech-tag">Whole Exome Sequencing</span>
                        <span class="tech-tag">Resistance Mechanisms</span>
                        <span class="tech-tag">Comparative Genomics</span>
                        <span class="tech-tag">Pathway Analysis</span>
                        <span class="tech-tag">Clinical Validation</span>
                    </div>
                </div>

                <!-- Project: CRISPR Screens -->
                <div class="project-card">
                    <h3>CRISPR Screening of KRAS Inhibitors</h3>
                    <h4>Pan-RAS and KRAS Mutant-Selective Inhibition Analysis</h4>
                    <div class="project-description">
                        We conduct large-scale CRISPR knockout screens to identify genetic dependencies and resistance 
                        mechanisms for both pan-RAS inhibitors and KRAS mutant-selective inhibitors in pancreatic 
                        cancer cell lines. This systematic approach reveals vulnerabilities that can be exploited 
                        for combination therapies.
                    </div>

                    <div class="project-details">
                        <h5>CRISPR Screen Design</h5>
                        <ul class="methodology-list">
                            <li>Genome-wide CRISPR knockout screens in multiple pancreatic cancer cell lines</li>
                            <li>Comparative analysis of pan-RAS vs. mutant-selective inhibitor responses</li>
                            <li>Time-course analysis to identify early and late resistance mechanisms</li>
                            <li>Drug dose response screening to identify synergistic combinations</li>
                            <li>Functional validation of top candidate genes</li>
                        </ul>
                    </div>

                    <div class="screen-results-grid">
                        <div class="screen-result-card">
                            <i class="fas fa-bullseye" style="font-size: 2rem; color: var(--primary-color); margin-bottom: 1rem;"></i>
                            <h4>Synthetic Lethal Targets</h4>
                            <p>Genes essential only in KRAS mutant context</p>
                        </div>
                        <div class="screen-result-card">
                            <i class="fas fa-shield-alt" style="font-size: 2rem; color: var(--primary-color); margin-bottom: 1rem;"></i>
                            <h4>Resistance Genes</h4>
                            <p>Genes that protect against KRAS inhibition</p>
                        </div>
                        <div class="screen-result-card">
                            <i class="fas fa-link" style="font-size: 2rem; color: var(--primary-color); margin-bottom: 1rem;"></i>
                            <h4>Combination Targets</h4>
                            <p>Genes for synergistic drug combinations</p>
                        </div>
                        <div class="screen-result-card">
                            <i class="fas fa-route" style="font-size: 2rem; color: var(--primary-color); margin-bottom: 1rem;"></i>
                            <h4>Pathway Dependencies</h4>
                            <p>Essential signaling pathways in resistance</p>
                        </div>
                    </div>

                    <div class="impact-highlight">
                        <h4>Therapeutic Innovation</h4>
                        <p>
                            Our CRISPR screens have identified several promising combination therapy opportunities 
                            that are now being tested in preclinical models and clinical trials. These rational 
                            combinations have the potential to prevent resistance and improve patient outcomes 
                            compared to KRAS inhibitor monotherapy.
                        </p>
                    </div>

                    <div class="tech-stack">
                        <span class="tech-tag">CRISPR Screening</span>
                        <span class="tech-tag">Pan-RAS Inhibitors</span>
                        <span class="tech-tag">Synthetic Lethality</span>
                        <span class="tech-tag">Combination Therapy</span>
                        <span class="tech-tag">Drug Synergy</span>
                    </div>
                </div>

                <!-- Project: PhageDisplay and Mass Spec -->
                <div class="project-card">
                    <h3>Target Discovery Through PhageDisplay and Mass Spectrometry</h3>
                    <div class="project-description">
                        We employ complementary approaches of PhageDisplay antibody screening and quantitative mass 
                        spectrometry to identify novel cell surface targets and understand protein-level changes during 
                        KRAS inhibition and resistance development.
                    </div>

                    <div class="project-details">
                        <h5>Integrated Discovery Pipeline</h5>
                        <ul class="methodology-list">
                            <li>Large-scale phage display library screening on pancreatic cancer cell lines</li>
                            <li>Quantitative proteomics analysis under various drug concentrations</li>
                            <li>Time-course analysis of protein expression changes during treatment</li>
                            <li>Cell surface proteome enrichment for ADC target identification</li>
                            <li>Post-translational modification analysis (phosphoproteomics, ubiquitinomics)</li>
                            <li>Antibody affinity maturation and characterization</li>
                        </ul>
                    </div>

                    <div class="target-discovery">
                        <h4>Novel Target Discovery</h4>
                        <p>
                            Our integrated approach has identified several previously unknown cell surface proteins 
                            that are specifically expressed or upregulated in KRAS-driven pancreatic cancers. 
                            These targets represent opportunities for developing highly specific antibody-drug 
                            conjugates that can deliver cytotoxic payloads directly to cancer cells.
                        </p>
                    </div>

                    <div class="tech-stack">
                        <span class="tech-tag">PhageDisplay</span>
                        <span class="tech-tag">Mass Spectrometry</span>
                        <span class="tech-tag">Antibody Screening</span>
                        <span class="tech-tag">ADC Development</span>
                        <span class="tech-tag">Phosphoproteomics</span>
                    </div>
                </div>
            </div>

            <!-- Data Integration Hub -->
            <div class="research-section">
                <h2>Pancreatic Cancer Data Repository</h2>
                <div class="project-card">
                    <h3>Hale Center Clinical Trial Data Integration</h3>
                    <div class="project-description">
                        We are building a comprehensive data repository that integrates multi-modal immune profiling data 
                        from ongoing clinical trials at the Hale Center for Pancreatic Cancer. This resource will serve 
                        as a foundation for AI-driven discovery and enable cross-trial comparisons and meta-analyses.
                    </div>

                    <div class="project-details">
                        <h5>Repository Components</h5>
                        <ul class="methodology-list">
                            <li>Standardized data collection protocols across clinical trials</li>
                            <li>Multi-modal data integration (genomics, proteomics, imaging)</li>
                            <li>Longitudinal patient tracking and outcome correlation</li>
                            <li>AI-ready data formatting and annotation</li>
                            <li>Secure, HIPAA-compliant data storage and access systems</li>
                            <li>Collaborative research platform for multi-institutional studies</li>
                        </ul>
                    </div>

                    <div class="impact-highlight">
                        <h4>Research Acceleration</h4>
                        <p>
                            This repository will dramatically accelerate pancreatic cancer research by providing researchers 
                            with access to high-quality, standardized datasets. The integration of multiple data types and 
                            clinical outcomes will enable machine learning approaches that would be impossible with smaller, 
                            single-trial datasets.
                        </p>
                    </div>

                    <div class="tech-stack">
                        <span class="tech-tag">Clinical Trials</span>
                        <span class="tech-tag">Data Integration</span>
                        <span class="tech-tag">Standardization</span>
                        <span class="tech-tag">Multi-modal Data</span>
                        <span class="tech-tag">Research Infrastructure</span>
                    </div>
                </div>
            </div>

            <!-- Methodological Innovations -->
            <div class="research-section">
                <h2>Methodological Innovations</h2>
                <div class="project-card">
                    <h3>Advanced Computational Approaches</h3>
                    <div class="project-description">
                        Our research develops novel computational methods specifically designed for integrative analysis 
                        of pancreatic cancer data. These methodological innovations enable more accurate understanding 
                        of tumor biology, immune interactions, and drug responses.
                    </div>

                    <div class="project-details">
                        <h5>Novel Analytical Methods</h5>
                        <ul class="methodology-list">
                            <li>Multi-modal data integration algorithms for immune and genomic profiling</li>
                            <li>Longitudinal modeling of treatment responses and resistance evolution</li>
                            <li>Network analysis of T-cell receptor repertoire and signaling pathways</li>
                            <li>Machine learning models for biomarker discovery and validation</li>
                            <li>Causal inference methods for treatment effect estimation</li>
                            <li>AI-driven target identification and drug design</li>
                        </ul>
                    </div>

                    <div class="tech-stack">
                        <span class="tech-tag">Algorithm Development</span>
                        <span class="tech-tag">Multi-modal Integration</span>
                        <span class="tech-tag">Longitudinal Analysis</span>
                        <span class="tech-tag">Network Analysis</span>
                        <span class="tech-tag">Causal Inference</span>
                        <span class="tech-tag">AI/ML Models</span>
                    </div>
                </div>
            </div>

            <!-- Clinical Translation -->
            <div class="research-section">
                <h2>Clinical Translation & Impact</h2>
                <div class="project-card">
                    <h3>From Discovery to Patient Care</h3>
                    <div class="project-description">
                        Our research is designed with clinical translation as a primary goal. We work closely with 
                        clinicians, pharmaceutical companies, and regulatory agencies to ensure that our discoveries 
                        can be rapidly translated into new treatments and diagnostic tools for pancreatic cancer patients.
                    </div>

                    <div class="project-details">
                        <h5>Active Clinical Collaborations</h5>
                        <ul style="list-style-type: disc; padding-left: 2rem;">
                            <li><strong>Dr. Stephanie Dougan</strong> - Medical Oncology, immunotherapy clinical trials</li>
                            <li><strong>Dr. Brian Wolpin</strong> - Pancreatic cancer clinical research</li>
                            <li><strong>Dr. Jonathan Nowak</strong> - Pathology and biomarker development</li>
                            <li><strong>Revolution Medicines</strong> - RMC-6236 clinical trial analysis</li>
                            <li><strong>Hale Center Clinical Teams</strong> - Multi-institutional clinical trial network</li>
                            <li><strong>Pharmaceutical Partners</strong> - ADC development and combination therapy trials</li>
                        </ul>
                    </div>

                    <div class="clinical-application">
                        <h4>Direct Patient Impact</h4>
                        <p>
                            Our research directly informs clinical trial design and patient treatment decisions at 
                            Dana-Farber and partner institutions. Several biomarkers and therapeutic targets identified 
                            through our work are now being tested in clinical trials, with the goal of improving 
                            outcomes for pancreatic cancer patients who currently have limited treatment options.
                        </p>
                    </div>
                </div>
            </div>

            <!-- Key Publications & Software -->
            <div class="research-section">
                <h2>Publications, Software & Intellectual Property</h2>
                <div class="project-card">
                    <h3>Key Research Outputs</h3>
                    <div class="project-details">
                        <h5>Manuscripts in Preparation</h5>
                        <ul style="list-style-type: disc; padding-left: 2rem;">
                            <li><strong>Integrative immune profiling in pancreatic cancer</strong> - Nature Immunology 2025</li>
                            <li><strong>CRISPR screening reveals vulnerabilities in KRAS-driven pancreatic cancer</strong> - Nature Cancer 2025</li>
                            <li><strong>Mechanisms of resistance to pan-RAS inhibition</strong> - Cancer Cell 2025</li>
                            <li><strong>Foundation models for immunotherapy prediction</strong> - Nature Medicine 2025</li>
                            <li><strong>PhageDisplay identification of novel ADC targets</strong> - Nature Biotechnology 2025</li>
                            <li><strong>TCR repertoire dynamics during treatment</strong> - Cell 2025</li>
                        </ul>
                    </div>

                    <div class="project-details">
                        <h5>Software & Data Resources</h5>
                        <ul style="list-style-type: disc; padding-left: 2rem;">
                            <li><strong>ImmuneProfiler Suite</strong> - Comprehensive toolkit for immune profiling analysis</li>
                            <li><strong>CRISPR-Analytics Suite</strong> - Pipeline for CRISPR screen analysis</li>
                            <li><strong>TCR-Analytics</strong> - T-cell receptor repertoire analysis pipeline</li>
                            <li><strong>Resistance Predictor</strong> - ML models for resistance prediction</li>
                            <li><strong>ADC Target Database</strong> - Curated database of cell surface targets</li>
                            <li><strong>Drug Combination Optimizer</strong> - Tools for rational combination design</li>
                            <li><strong>Pancreatic Cancer Immune Atlas</strong> - Curated repository of immune profiling data</li>
                            <li><strong>Multi-Modal Immune Integration Platform</strong> - Framework for integrating diverse data types</li>
                        </ul>
                    </div>

                    <div class="project-details">
                        <h5>Patent Applications</h5>
                        <ul style="list-style-type: disc; padding-left: 2rem;">
                            <li><strong>Novel ADC targets in pancreatic cancer</strong> - Patent application filed 2024</li>
                            <li><strong>Biomarkers for KRAS inhibitor resistance</strong> - Patent application in preparation</li>
                            <li><strong>Combination therapy strategies</strong> - Patent applications filed 2024-2025</li>
                            <li><strong>Immune signature predictors</strong> - Patent application in preparation 2025</li>
                        </ul>
                    </div>
                </div>
            </div>

            <!-- Future Directions -->
            <div class="research-section">
                <h2>Future Directions</h2>
                <div class="impact-highlight">
                    <h4>Next-Generation Pancreatic Cancer Research</h4>
                    <p>
                        We are developing the next generation of integrative approaches that combine spatial omics, 
                        large language models, and foundation models for comprehensive understanding of pancreatic 
                        cancer biology. Our future work will focus on:
                    </p>
                    <ul style="list-style-type: disc; padding-left: 2rem; margin-top: 1rem;">
                        <li>AI-driven prediction of drug responses and resistance evolution</li>
                        <li>Spatial multi-omics integration for tumor microenvironment analysis</li>
                        <li>Personalized combination therapy design using machine learning</li>
                        <li>Real-time treatment monitoring through liquid biopsy and AI analysis</li>
                        <li>Development of next-generation immunotherapies for pancreatic cancer</li>
                        <li>Creation of digital twins for patient-specific treatment optimization</li>
                    </ul>
                </div>
            </div>

            <!-- Back Navigation -->
            <div class="text-center" style="margin-top: 3rem;">
                <a href="../index.html#research" class="btn btn-secondary">Back to Research Overview</a>
            </div>
        </div>
    </div>

    <!-- Footer -->
    <footer class="footer">
        <div class="container">
            <div class="footer-content">
                <div class="footer-logo">
                    <h3>Cristea Lab</h3>
                    <p>AI Cancer Genomics Research</p>
                </div>
                <div class="footer-links">
                    <a href="https://www.dana-farber.org" target="_blank">Dana-Farber Cancer Institute</a>
                    <a href="https://www.harvard.edu" target="_blank">Harvard University</a>
                </div>
                <div class="footer-social">
                    <a href="#" class="social-link"><i class="fab fa-twitter"></i></a>
                    <a href="#" class="social-link"><i class="fab fa-github"></i></a>
                    <a href="#" class="social-link"><i class="fab fa-linkedin"></i></a>
                </div>
            </div>
            <div class="footer-bottom">
                <p>&copy; 2024 Cristea Lab. All rights reserved.</p>
            </div>
        </div>
    </footer>

    <script src="../script.js"></script>
</body>
</html>